Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.56
- Piotroski Score 5.00
- Grade Market Perform
- Symbol (BMY)
- Company Bristol-Myers Squibb Company
- Price $57.89
- Changes Percentage (-0.59%)
- Change -$0.35
- Day Low $57.67
- Day High $58.82
- Year High $61.08
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
- Last Earnings 09/10/2024
- Ex-Dividend for 5/16 Dividend 10/04/2024
- Dividend Payable 11/01/2024
- Today N/A
- Next Earnings (Estimated) 02/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $66.50
- High Stock Price Target $85.00
- Low Stock Price Target $41.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.10
- Trailing P/E Ratio -13.38
- Forward P/E Ratio -13.38
- P/E Growth -13.38
- Net Income $8.03 B
Income Statement
Quarterly
Annual
Latest News of BMY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Bloomsbury Publishing Plc's (LON:BMY) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Bloomsbury Publishing's stock has increased by 2.4% in three months. Analyzing its Return on Equity (ROE) reveals a strong 19% figure, indicating efficient profit generation and growth potential....
By Yahoo! Finance | 1 week ago -
What's Next For BMY Stock After An Upbeat Q3?
Bristol Myers Squibb exceeded Q3 revenue and earnings estimates, raising its full-year outlook. The stock gained 6% in a week. Revenue grew 8% y-o-y, with strong performance in growth portfolio. Adjus...
By Forbes | 2 weeks ago -
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy Right Now?
The article discusses the current state of the pharmaceutical industry, highlighting the growth potential and challenges faced by companies like Bristol-Myers Squibb. It emphasizes the importance of b...
By Yahoo! Finance | 2 weeks ago
